Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Rbv Dasabuvir'

Rbv Dasabuvir published presentations and documents on DocSlides.

HCV Clinical Management TRAINER(S)

HCV Clinical Management TRAINER(S)

  • danika-pritchard
  • 0 Slides

IAPAC African Regional Capacity-Building Hub. Bas...

Updates in Treatment of Hepatitis C

Updates in Treatment of Hepatitis C

  • cheryl-pisano
  • 0 Slides

Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...

Hepatitis C Imtiaz Alam, M.D.

Hepatitis C Imtiaz Alam, M.D.

  • olivia-moreira
  • 0 Slides

Medical Director, Austin Hepatitis Center. 1. Hep...

HCV Clinical Management TRAINER(S)

HCV Clinical Management TRAINER(S)

  • trish-goza
  • 0 Slides

IAPAC African Regional Capacity-Building Hub. Bas...

Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care

Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care

  • webraph
  • 50 Slides

Sameh W. Boktor, MD, MPH. Medical Epidemiologist. ...

M.W. Fried , 1 M. Buti,

M.W. Fried , 1 M. Buti,

  • iamamercy
  • 18 Slides

2. G.J. Dore,. 3. P. Ferenci,. 4. . I. Jacobson...

522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc

522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc

  • daisy
  • 7 Slides

B7AB8DW10--62712/0216U28411204- f-25189455DVReWbVT...

Are (exogenous) interferons

Are (exogenous) interferons

  • amey
  • 35 Slides

really necessary?. Peter . Ferenci. Medical Univer...

NS5A and polymerase inhibitors

NS5A and polymerase inhibitors

  • LoveBug
  • 16 Slides

Mark Sulkowski, MD. Professor of Medicine. Johns H...

How to optimize treatment of G1 patients?

How to optimize treatment of G1 patients?

  • KissesForYou
  • 12 Slides

Prof. G. K. K. Lau 2012. Standard of care (SOC) ...

Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology

Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology

  • badra
  • 33 Slides

Duke University School of Medicine. Durham, North ...

Pharmacometrics and Biostatistics Interactions at the FDA

Pharmacometrics and Biostatistics Interactions at the FDA

  • byrne
  • 29 Slides

Jeffry Florian, Ph.D.. Division of Pharmacometrics...

FISSION Design Objective

FISSION Design Objective

  • travis
  • 6 Slides

Non . inferiority. of SOF + RBV : SVR. 12. (. 2-...

Sofosbuvir

Sofosbuvir

  • conchita-marotz
  • 9 Slides

ELECTRON (Overview): 6 parts, 22 arms. Phase . 2....

Treatment of Hepatitis C in patients with

Treatment of Hepatitis C in patients with

  • tatyana-admore
  • 31 Slides

thalassaemia. . Where . are we now?. Telaprevir ....

Advances in Hepatitis C Identification and Treatment

Advances in Hepatitis C Identification and Treatment

  • giovanna-bartolotta
  • 67 Slides

Developed by Camilla S. Graham, MD, BIDMC, 5/5/15...

Update on the HCV Antiviral Pipeline

Update on the HCV Antiviral Pipeline

  • natalia-silvester
  • 14 Slides

Todd S. Wills, MD. SPNS HCV Treatment Expansion I...

TURQUOISE-I:

TURQUOISE-I:

  • tawny-fly
  • 18 Slides

SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASA...

CURRY

CURRY

  • faustina-dinatale
  • 13 Slides

Design. Open-label. CURRY . Study. : SOF + RBV fo...

Daclatasvir in Combination With Sofosbuvir

Daclatasvir in Combination With Sofosbuvir

  • mitsue-stanley
  • 15 Slides

With Or Without Ribavirin Is Safe and Efficacious...

26/07/2013

26/07/2013

  • alida-meadow
  • 14 Slides

1. Le 29-01-2015. Les anticorps neutralisants ant...

Management of HCV in Co-Infected Patients

Management of HCV in Co-Infected Patients

  • danika-pritchard
  • 22 Slides

Marie-Louise Vachon, MD, . MSc. Division of . Inf...

The Resource Based View of the Firm (RBV)

The Resource Based View of the Firm (RBV)

  • celsa-spraggs
  • 36 Slides

B290. The object of strategic analysis…. Explai...

Ombitasvir-

Ombitasvir-

  • min-jolicoeur
  • 23 Slides

Paritaprevir. -. Ritonavir (. Technivie. ). Prepa...

OBV/PTV/r

OBV/PTV/r

  • kittie-lecroy
  • 7 Slides

+ DSV + RBV. No randomisation. Open-label. TOPAZ-...

Simeprevir in

Simeprevir in

  • ellena-manuel
  • 14 Slides

Genotype . 1 . (. Viral . Relapsers. ). PROMISE ....

Sofosbuvir in

Sofosbuvir in

  • giovanna-bartolotta
  • 9 Slides

Genotype . 2. . or 3 . FUSION. Trial. Phase . ...

Peginterferon alfa-2a (

Peginterferon alfa-2a (

  • tatyana-admore
  • 46 Slides

Pegasys. ). Prepared by: David Spach, MD & H....

Are Pan-Genotypic Therapies Ready for Prime Time?

Are Pan-Genotypic Therapies Ready for Prime Time?

  • lois-ondreau
  • 21 Slides

3. Rd. International . HIV/Hepatitis . Coinfecti...

No randomisation

No randomisation

  • tatiana-dople
  • 6 Slides

N = 100. W12. W24. Arm B: . compensated cirrhosis...

Ledipasvir-Sofosbuvir (

Ledipasvir-Sofosbuvir (

  • lindy-dunigan
  • 127 Slides

Harvoni. ). Prepared by: . David H. Spach, MD and...

Daclatasvir in Combination With Sofosbuvir

Daclatasvir in Combination With Sofosbuvir

  • mitsue-stanley
  • 15 Slides

With Or Without Ribavirin Is Safe and Efficacious...

OBV/PTV/r

OBV/PTV/r

  • conchita-marotz
  • 5 Slides

OBV/PTV/r + RBV. Randomisation*. 1 : 1. Open labe...

MK3 + RBV

MK3 + RBV

  • jane-oiler
  • 5 Slides

N = 45. N = 49. W24. W16. MK3. > . 18 years. H...

Placebo + PR

Placebo + PR

  • aaron
  • 6 Slides

W24. DCV + PR. Placebo + PR. Yes. Dore GJ. Gastro...

2013 Asilomar HIV Medical Update

2013 Asilomar HIV Medical Update

  • luanne-stotts
  • 74 Slides

David Spach, MD. Clinical Director, Northwest AET...

Sofosbuvir + Peginterferon + Ribavirin in Genotype 2

Sofosbuvir + Peginterferon + Ribavirin in Genotype 2

  • debby-jeon
  • 10 Slides

. or 3 . LONESTAR-2. Phase 2. Treatment. . Exp...

ALLY-1

ALLY-1

  • stefany-barnette
  • 6 Slides

Design. Objective. SVR. 12. (HCV RNA < 25 IU/...

Sofosbuvir, Ribavirin, GS

Sofosbuvir, Ribavirin, GS

  • min-jolicoeur
  • 7 Slides

-. 0938 in GT 1-4. QUANTUM. Phase . 2b. Treatment...

Not randomised Open-label

Not randomised Open-label

  • cheryl-pisano
  • 0 Slides

18-70 years. HCV genotype 1 or 3. Naïve or failu...

Copyright © 2024 DocSlides. All Rights Reserved